CN117642174A - 用于治疗糖尿病性肾病的il1ra来源的肽 - Google Patents

用于治疗糖尿病性肾病的il1ra来源的肽 Download PDF

Info

Publication number
CN117642174A
CN117642174A CN202180100484.5A CN202180100484A CN117642174A CN 117642174 A CN117642174 A CN 117642174A CN 202180100484 A CN202180100484 A CN 202180100484A CN 117642174 A CN117642174 A CN 117642174A
Authority
CN
China
Prior art keywords
compound
amino acid
seq
peptide
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180100484.5A
Other languages
English (en)
Chinese (zh)
Inventor
E·斯坦尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therods Private LLC
Original Assignee
Therods Private LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therods Private LLC filed Critical Therods Private LLC
Publication of CN117642174A publication Critical patent/CN117642174A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202180100484.5A 2021-07-13 2021-07-13 用于治疗糖尿病性肾病的il1ra来源的肽 Pending CN117642174A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2021/069450 WO2023284947A1 (en) 2021-07-13 2021-07-13 Il1ra derived peptides for treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
CN117642174A true CN117642174A (zh) 2024-03-01

Family

ID=76958978

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180100484.5A Pending CN117642174A (zh) 2021-07-13 2021-07-13 用于治疗糖尿病性肾病的il1ra来源的肽

Country Status (8)

Country Link
US (1) US20240216464A1 (https=)
EP (1) EP4351617B1 (https=)
JP (1) JP7839260B2 (https=)
CN (1) CN117642174A (https=)
AU (1) AU2021455992A1 (https=)
CA (1) CA3226176A1 (https=)
ES (1) ES3026437T3 (https=)
WO (1) WO2023284947A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
KR101317045B1 (ko) * 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
ES2600616T3 (es) * 2011-03-14 2017-02-10 Phlogo Aps Antagonistas del receptor de la interleucina-1
WO2017063657A1 (en) * 2015-10-14 2017-04-20 Phlogo Aps Il1ra-derived peptide antagonist
WO2018022982A1 (en) * 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Also Published As

Publication number Publication date
AU2021455992A1 (en) 2024-01-18
CA3226176A1 (en) 2023-01-19
JP7839260B2 (ja) 2026-04-01
EP4351617B1 (en) 2025-03-26
WO2023284947A1 (en) 2023-01-19
EP4351617C0 (en) 2025-03-26
JP2024525669A (ja) 2024-07-12
EP4351617A1 (en) 2024-04-17
ES3026437T3 (en) 2025-06-11
US20240216464A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
Rochester et al. Eosinophil-fibroblast interactions. Granule major basic protein interacts with IL-1 and transforming growth factor-β in the stimulation of lung fibroblast IL-6-type cytokine production
CN109475592B (zh) 用于治疗糖尿病和慢性肾病的新型脂肪酸修饰的尿皮质素-2类似物
CN103476933B (zh) 白介素1受体的拮抗剂
US20200188471A1 (en) Application of selective tnfr1 antagonist peptide sn10 in preparation of drugs for preventing and treating rheumatoid arthritis
KR20170023066A (ko) 글루카곤 수용체 길항 항체를 이용한 제 1 형 당뇨병의 치료 방법
CN103030687A (zh) 青环海蛇抗炎活性肽Hydrostatin-SN1及其编码基因和在制药中的应用
CN117642174A (zh) 用于治疗糖尿病性肾病的il1ra来源的肽
CN112898405B (zh) 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
CN112368294B (zh) 用于治疗风湿性关节炎的肽以及其用途
CN112220913A (zh) TFF2蛋白和IFN-κ蛋白联用在治疗新型冠状病毒感染中的应用
US20240325496A1 (en) Cxc chemokine agonists and antagonists in covid-19 disease and diagnostic assays
JP7634138B1 (ja) 糖尿病性腎症の治療における使用のためのｉｌ－４由来ペプチド断片
CA3244198C (en) Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy
US20240174728A1 (en) A use of a polypeptide compound in the preparation of drugs for preventing or treating inflammatory bowel diseases and related intestinal fibrosis
KR20250071239A (ko) Crrl 191, 심방 나트륨 이뇨 펩티드(anp) 유사체 및 구아닐릴 시클라제 수용체(gc-a)활성화제를 이용한 조성물 및 치료 방법
Wang et al. Characterization of the Active Components of the Multimerized sTNFRII-Adiponectin Fusion Protein Showing Both TNFα-Antagonizing and Glucose Uptake-Promoting Activities
AU2021235254A1 (en) Compositions and methods relating to the treatment of diseases
WO2019058107A1 (en) Peptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination